title: Patient survival and renal recovery in acute renal failure: randomized comparison of cellulose acetate and polysulfone membrane dialyzers.
abstract: OBJECTIVE
  To investigate survival and renal recovery after dialysis in patients with acute renal failure with use of synthetic membranes compared with substituted cellulose membranes.
  
  
  METHODS
  We prospectively studied survival and recovery of renal function of 66 patients with acute renal failure who required intermittent hemodialysis. Patients were randomized to exclusive treatment with either cellulose acetate (CA) or polysulfone (PS) hemodialysis membranes. Additionally, markers of biocompatibility (complement, leukocyte counts, cytokine concentration) were measured at initiation and 1 hour after initiation of dialysis among 10 patients equally distributed between the CA and PS groups.
  
  
  RESULTS
  The cohorts were indistinguishable with respect to age, sex, presence of diabetes mellitus, Acute Physiology and Chronic Health Evaluation II scores, percentage in the intensive care unit (ICU), and adequacy of dialysis. Survival (76% CA, 73% PS; P=.78) and recovery of renal function at 30 days (58% CA, 39% PS; P=.14) were not statistically different in the 2 groups. Among 26 CA patients and 27 PS patients treated in the ICU, survival was not statistically different (73% CA, 67% PS; P=.61); however, the proportion of patients recovering renal function suggested a benefit favoring CA membranes (65% CA, 37% PS; P=.04). Additionally, markers of biocompatibility were not significantly different between groups among the 10 patients equally distributed between the CA and PS groups.
  
  
  CONCLUSIONS
  Overall clinical outcomes among patients with acute renal failure treated with CA hemodialysis membranes and those treated with PS membranes were not significantly different. The observed advantage favoring renal recovery among this ICU population treated with CA hemodialysis membranes warrants further investigation.
authors.affiliation: Division of Nephrology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA. albright.robert@mayo.edu
authors.forename: R C
authors.initials: RC
authors.lastname: Albright
authors.forename: J M
authors.initials: JM
authors.lastname: Smelser
authors.forename: J T
authors.initials: JT
authors.lastname: McCarthy
authors.forename: H A
authors.initials: HA
authors.lastname: Homburger
authors.forename: E J
authors.initials: EJ
authors.lastname: Bergstralh
authors.forename: T S
authors.initials: TS
authors.lastname: Larson
mesh_terms: D058186:Acute Kidney Injury / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D000368:Aged; D002482:Cellulose / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D011108:Polymers; D011446:Prospective Studies; D006435:Renal Dialysis; D013450:Sulfones; D016019:Survival Analysis
chemical_list: D018836:Inflammation Mediators; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; C017662:polysulfone P 1700; C005062:acetylcellulose; D002482:Cellulose